Benztropine Mesylate

Aspen Oss B.V offers a wide range of products which includes testosterone phenylpropionate. Therapeutic category: steroid hormones. Contact us for more information.

Aspen Oss B.V offers a wide range of products which includes testosterone propionate. Therapeutic category: steroid hormones. Contact us for more information.

Aspen Oss B.V offers a wide range of products which includes testosterone undecanoate. Therapeutic category: steroid hormones. Contact us for more information.

Aspen Oss B.V offers a wide range of products which includes mirtazapine. Therapeutic category: central nervous system. Contact us for more information.

Aspen Oss B.V offers a wide range of products which includes rocuronium bromide. Therapeutic category: steroid hormones. Contact us for more information.

Azathioprine is part of the API portfolio of Fine Chemicals Corporation. 

Available filings: 
CEP/ASMF
US-DMF 

This API is part of the FCC product portfolio

Specific Disclaimer. This active ingredient could be protected by a patent in force and would be therefore developed on request exclusively for the purposes stated in Article 10.6 of the Directive 2001/83/EC as amended by the Directive 2004/27/EC (Bolar provision). No activity will be performed with the ac...

This API is part of the FCC product portfolio

This API is part of the FCC product portfolio

This API is part of the FCC product portfolio

This API is part of the FCC product portfolio

Our Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS) combines the advantages of the classical solution-phase synthesis with the solid-phase approach. 

Aspen is a global specialty and branded pharmaceutical company committed to promoting access to medicines and improving the health of patients across the world through our high quality, affordable products. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.

While in the past, much of the discussion around sustainability in the pharmaceutical industry rightly focused on efforts to minimize the environmental impact of drug production, the needle has now shifted. There are signs that companies not only understand that it represents one of the world’s biggest challenges moving forward, but also that they are starting to incorporate sustainability practices into a much broader suite of operations.

Panel at CPHI Festival of Pharma discusses options for companies to ensure robust supply chains and reduce overseas supply dependency